[HTML][HTML] Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis

IL Alberts, SE Seide, C Mingels, KP Bohn, K Shi… - European journal of …, 2021 - Springer
Purpose Many radiotracers are currently available for the detection of recurrent prostate
cancer (rPC), yet many have not been compared head-to-head in comparative imaging …

[HTML][HTML] Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on ClinicalTrials. gov

C Zippel, SC Ronski, S Bohnet-Joschko, FL Giesel… - Pharmaceuticals, 2020 - mdpi.com
The recent development of dedicated prostate-specific membrane antigen (PSMA) targeted
radioligands shows the potential to change and improve the diagnosis and therapy of …

PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A …

N Tan, U Oyoyo, N Bavadian, N Ferguson… - Radiology, 2020 - pubs.rsna.org
Background National guidelines endorse fluorine 18 (18F) fluciclovine PET/CT for the
detection of prostate cancer (PCa) in men with biochemically recurrent PCa. The …

[HTML][HTML] Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov …

I Alberts, C Mingels, HD Zacho, S Lanz… - European journal of …, 2021 - Springer
Abstract Purpose Amongst others,[68 Ga] Ga-PSMA-11 and [18 F] PSMA-1007 are available
for the detection of recurrent prostate cancer (rPC). There are currently limited data …

[HTML][HTML] Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis

G Treglia, S Annunziata, DA Pizzuto, L Giovanella… - Cancers, 2019 - mdpi.com
Background: The use of radiolabeled prostate-specific membrane antigen positron emission
tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate …

[HTML][HTML] Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

A Afshar-Oromieh, T Holland-Letz, FL Giesel… - European journal of …, 2017 - Springer
Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

[HTML][HTML] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

A Afshar-Oromieh, E Avtzi, FL Giesel… - European journal of …, 2015 - Springer
Purpose Since the introduction of positron emission tomography (PET) imaging with 68 Ga-
PSMA-HBED-CC (= 68 Ga-DKFZ-PSMA-11), this method has been regarded as a significant …

[HTML][HTML] Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis

G Treglia, RP Mestre, M Ferrari, DG Bosetti… - American journal of …, 2019 - ncbi.nlm.nih.gov
Both radiolabelled choline and prostate specific membrane antigen (PSMA) positron
emission tomography/computed tomography (PET/CT) could be used in patients with …

Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience

A Afshar-Oromieh, U Haberkorn, HP Schlemmer… - European journal of …, 2014 - Springer
Abstract Purpose 68 Ga-labelled HBED-CC-PSMA is a highly promising tracer for imaging
recurrent prostate cancer (PCa). The intention of this study was to evaluate the feasibility of …

Theranostics for advanced prostate cancer: current indications and future developments

A Farolfi, W Fendler, A Iravani, U Haberkorn… - European urology …, 2019 - Elsevier
Abstract Context Advanced prostate cancer (PCa) is a prominent cause of cancer death in
men; positron emission tomography (PET) imaging may play a relevant role in detecting …